Cargando…
Recent Progress in the Development of Opaganib for the Treatment of Covid-19
The Covid-19 pandemic driven by the SARS-CoV-2 virus continues to exert extensive humanitarian and economic stress across the world. Although antivirals active against mild disease have been identified recently, new drugs to treat moderate and severe Covid-19 patients are needed. Sphingolipids regul...
Autores principales: | Smith, Charles D, Maines, Lynn W, Keller, Staci N, Katz Ben-Yair, Vered, Fathi, Reza, Plasse, Terry F, Levitt, Mark L |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9288228/ https://www.ncbi.nlm.nih.gov/pubmed/35855741 http://dx.doi.org/10.2147/DDDT.S367612 |
Ejemplares similares
-
The Sphingosine Kinase 2 Inhibitor Opaganib Protects Against Acute Kidney Injury in Mice
por: Maines, Lynn W, et al.
Publicado: (2022) -
Opaganib Protects against Radiation Toxicity: Implications for Homeland Security and Antitumor Radiotherapy
por: Maines, Lynn W., et al.
Publicado: (2022) -
Opaganib in Coronavirus Disease 2019 Pneumonia: Results of a Randomized, Placebo-Controlled Phase 2a Trial
por: Winthrop, Kevin L, et al.
Publicado: (2022) -
Organometallic small molecule kinase inhibitors – direct incorporation of Re and (99m)Tc into Opaganib®
por: Lengacher, Raphael, et al.
Publicado: (2021) -
A randomized, placebo-controlled pilot study of upamostat, a host-directed serine protease inhibitor, for outpatient treatment of COVID-19
por: Plasse, Terry F, et al.
Publicado: (2023)